Olema director granted 29,500 stock options

Olema Pharmaceuticals director Cynthia M. Butitta received a grant of 29,500 stock options for common stock.

Rhea-AI Filing Summary

Olema Pharmaceuticals director Cynthia M. Butitta received a grant of 29,500 stock options for common stock. The options have an exercise price of $9.51 per share and were awarded as compensation, not through an open-market purchase.

The options vest in 12 equal monthly installments starting on June 18, 2026, as long as she continues in service. Any unvested portion will fully vest on the date of Olema’s next annual meeting of stockholders if the grant is not already fully vested by then.

Insider Trade Summary

Grant/Award: 29,500 shares

Grant/Award 1 txn

Insider BUTITTA CYNTHIA M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	29,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 29,500 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Options granted: 29,500 options Exercise price: $9.51 per share Underlying shares: 29,500 shares +3 more

6 metrics

Options granted 29,500 options Stock Option (right to buy) grant to director

Exercise price $9.51 per share Stock option strike price for Olema common stock

Underlying shares 29,500 shares Common stock underlying the option grant

Expiration date June 18, 2036 Option expiration for this grant

Monthly vesting schedule 12 installments Equal monthly vesting starting June 18, 2026

Post-transaction derivative holdings 29,500 options Total options held from this grant after transaction

Key Terms

Stock Option (right to buy), exercise price, vesting, annual meeting of stockholders, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "9.5100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares subject to the option vest in a series of 12 successive equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"Such shares vest in full on the date of the Issuer's next annual meeting of stockholders"

continuous service financial

"subject to the Reporting Person's continuous service through each applicable vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Olema Pharmaceuticals (OLMA) report for Cynthia M. Butitta?

Olema reported a grant of 29,500 stock options to director Cynthia M. Butitta. These options give her the right to buy common shares at a fixed price, representing equity-based compensation rather than an open-market purchase or sale.

What is the exercise price of the new Olema (OLMA) stock options granted to Cynthia M. Butitta?

The granted options have an exercise price of $9.51 per share. This means she can buy Olema common stock at $9.51 in the future once the options vest, regardless of the market price at that time.

How do Cynthia M. Butitta’s Olema (OLMA) stock options vest over time?

The 29,500 options vest in 12 equal monthly installments starting on June 18, 2026. Vesting requires her continuous service with Olema through each vesting date, gradually increasing her exercisable option position.

When do Cynthia M. Butitta’s Olema (OLMA) options fully vest if not already vested monthly?

Any remaining unvested options fully vest on the date of Olema’s next annual meeting of stockholders, if the grant is not already fully vested. This acceleration also depends on her continuous service through that vesting date.

Is Cynthia M. Butitta buying or selling Olema (OLMA) shares in this Form 4 filing?

This Form 4 reflects a grant of stock options, not a market buy or sell. She is receiving derivative rights to purchase shares in the future as compensation, rather than trading existing Olema stock in the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 05:29 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BUTITTA CYNTHIA M

(Last) (First) (Middle)

C/O OLEMA PHARMACEUTICALS, INC.

780 BRANNAN ST

(Street)

SAN FRANCISCO CALIFORNIA 94103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$9.51	06/18/2026		A		29,500		(1)	06/18/2036	Common Stock	29,500	$0	29,500	D

Explanation of Responses:

1. The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Shawnte Mitchell, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)